VAN ANDEL INSTITUTE®

FOUNDED BY JAY AND BETTY VAN ANDEL

IBC Meeting Minutes
Date: August 20, 2025
Location: Conf. Room 2102

Voting Members Present (9):
Michael Henderson, Ph.D. (Chair)
Glen Alberts, B.S.
Pamela Bartlett, B.S
Nicholas Burton, Ph.D.
Scott Bechaz, ILAM, RLATg
Craig Bickel, M.Div.
Angie Jason (non-voting)
Lauren Miedema, B.S., MPH
Sam Pinto, B.S. (Vice Chair)
Jennifer Steiner, Ph.D.

Voting Members Excused (2):
Matthew Donahue, MBA
Rachael Sheridan, Ph.D.

Christy Goss (guest)

Call to Order
Michael Henderson called the meeting to order at 9:04 a.m.

Meeting Minutes – Minutes from the IBC meeting on 06/18/25 were approved unanimously.
Vote: (9 Total) 9 Approve 0 Disapprove 0 Abstain 0 Recuse

New Business – Jennifer Steiner informed the committee of a wording addition in the IBC Tick@Lab project summary description. Angie Jason also informed the committee that a question will be added in the rDNA section regarding biological/toxins.

Protocol Reviews

A. Reference #25-0073 – Initial – Bangan Wang, Ph.D.
"Directed gene expression with enhancer-driven AAV delivery"
Primary Reviewer: Glen Alberts

The purpose of this protocol is to use engineered adeno-associated viruses to deliver transgenes for identifying and functionally validating novel cis-regulatory elements in specific brain cell populations, enabling downstream analysis of how DNA, RNA, and proteins interact within the nucleus to regulate cell function. AAV pools carrying fluorescent reporters or Cre recombinase under the control of brain cell-type-specific enhancers will be delivered retro-orbitally in mice to evaluate delivery efficiency, targeting specificity, and transgene expression. The CRISPR-Cas9 system will also be used to perturb the CREs/enhancer to evaluate our functional evaluation. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate, but the following clarifications must be provided.

1. General Information – The investigator was asked to specify which ABSL-2 surgery rooms will be used.
2. rDNA- The investigator was asked to attach plasmid maps, add gene/insert information, change to BSL2, describe AAV purification methodology, clarify enhancer sequences, change room location, deselect transgenic mouse.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 1
Containment Level: BSL1

Location Assessment: Phase 1, Level 4, Bay 15 - Dr. Bangan Wang lab spaces, ABSL-2 surgery rooms

Action: Modifications to secure approval.

Vote: (9 Total) 9 Approve 0 Disapprove 0 Abstain 0 Recuse

B. Reference #25-0019 – Initial – Derek Janssens, Ph.D.
"Transfecting MSCV MLL-ENL vectors into human cell lines"
Primary Reviewer: Jennifer Steiner

The purpose of this protocol is to investigate how different stages of leukemia development influence treatment resistance, we will introduce the *MLL::ENL* fusion into human myeloid leukemia cell lines using a MSCV retroviral transfection system. The GFP and/or HiBiT tag will be used to verify MLL::ENL fusion protein expression to explore the impact of this fusion on leukemia lineage plasticity. The transduction will occur in a BSL-2 safety cabinet dedicated to lentiviral and/or retroviral work. The members determined that the proposed study procedures, practices and the training and expertise of the personnel who will be conducting the study are appropriate.

Applicable section of the *NIH Guidelines* the research falls under: Section III-D-1.

Risk Group: 2
Containment Level: BSL2

Location Assessment: Room 5234 and room 5125W.

Action: Approved.

Vote: (9 Total) 9 Approve 0 Disapprove 0 Abstain 0 Recuse

Meeting was adjourned at 9:37 am